JP2022532812A - 抗ｉｌ１ｒａｐ抗体組成物 - Google Patents

抗ｉｌ１ｒａｐ抗体組成物 Download PDF

Info

Publication number
JP2022532812A
JP2022532812A JP2021507831A JP2021507831A JP2022532812A JP 2022532812 A JP2022532812 A JP 2022532812A JP 2021507831 A JP2021507831 A JP 2021507831A JP 2021507831 A JP2021507831 A JP 2021507831A JP 2022532812 A JP2022532812 A JP 2022532812A
Authority
JP
Japan
Prior art keywords
seq
sequence identity
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021507831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532812A5 (https=
JPWO2020035577A5 (https=
Inventor
ヨーラン・フォーシュバリ
ダーヴィド・リーバリ
シェル・ショーストローム
カーリン・ヴォン・ヴァーケンフェルト
Original Assignee
カンタージア アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カンタージア アクチエボラーグ filed Critical カンタージア アクチエボラーグ
Publication of JP2022532812A publication Critical patent/JP2022532812A/ja
Publication of JP2022532812A5 publication Critical patent/JP2022532812A5/ja
Publication of JPWO2020035577A5 publication Critical patent/JPWO2020035577A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021507831A 2018-08-16 2019-08-15 抗ｉｌ１ｒａｐ抗体組成物 Pending JP2022532812A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1850983 2018-08-16
PCT/EP2019/071974 WO2020035577A1 (en) 2018-08-16 2019-08-15 Anti-il1rap antibody compositions

Publications (3)

Publication Number Publication Date
JP2022532812A true JP2022532812A (ja) 2022-07-20
JP2022532812A5 JP2022532812A5 (https=) 2022-08-12
JPWO2020035577A5 JPWO2020035577A5 (https=) 2022-08-12

Family

ID=67667857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507831A Pending JP2022532812A (ja) 2018-08-16 2019-08-15 抗ｉｌ１ｒａｐ抗体組成物

Country Status (5)

Country Link
US (1) US12209131B2 (https=)
EP (1) EP3837283B1 (https=)
JP (1) JP2022532812A (https=)
CN (1) CN112638946A (https=)
WO (1) WO2020035577A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
US11970539B2 (en) * 2020-09-14 2024-04-30 Ichnos Sciences SA Antibodies that bind to IL1RAP and uses thereof
JP2024500920A (ja) * 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
US20240317868A1 (en) 2021-02-05 2024-09-26 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
JP2024520338A (ja) * 2021-05-21 2024-05-24 レオ ファーマ アクティーゼルスカブ 抗ｉｌ－１受容体アクセサリータンパク質抗体
CA3226673A1 (en) * 2021-07-21 2023-01-21 Stelexis Therapeutics, Llc Il1rap antibodies and uses thereof
CN115353566B (zh) * 2022-09-14 2023-05-09 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
CN116284401B (zh) * 2023-02-20 2024-09-24 中国人民解放军军事科学院军事医学研究院 人源抗il-1r3抗体及其应用
WO2024231251A1 (en) * 2023-05-05 2024-11-14 Cantargia Ab Anti-il1rap antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504172A (ja) * 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
JP2010116338A (ja) * 2008-11-12 2010-05-27 Evec Inc 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
JP2017515792A (ja) * 2014-03-05 2017-06-15 カンタージア アクチエボラーグ 抗ヒトインターロイキン−１受容体アクセサリータンパク質（ｉｌ１ ｒａｐ）抗体およびその使用
JP2017530692A (ja) * 2014-08-06 2017-10-19 カンタージア アクチエボラーグ 新規の抗体及びその使用
JP2019500869A (ja) * 2015-12-01 2019-01-17 ゲンマブ ビー．ブイ． 抗ｄｒ５抗体およびその使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
AU2016350705A1 (en) * 2015-11-02 2018-05-17 Janssen Pharmaceutica Nv Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
CA3084459A1 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504172A (ja) * 1992-06-30 1996-05-07 オンコロジクス，インコーポレイティド 抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
JP2010116338A (ja) * 2008-11-12 2010-05-27 Evec Inc 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
JP2017515792A (ja) * 2014-03-05 2017-06-15 カンタージア アクチエボラーグ 抗ヒトインターロイキン−１受容体アクセサリータンパク質（ｉｌ１ ｒａｐ）抗体およびその使用
JP2017530692A (ja) * 2014-08-06 2017-10-19 カンタージア アクチエボラーグ 新規の抗体及びその使用
JP2019500869A (ja) * 2015-12-01 2019-01-17 ゲンマブ ビー．ブイ． 抗ｄｒ５抗体およびその使用方法

Also Published As

Publication number Publication date
EP3837283A1 (en) 2021-06-23
CN112638946A (zh) 2021-04-09
WO2020035577A1 (en) 2020-02-20
EP3837283B1 (en) 2024-04-17
US20220267454A1 (en) 2022-08-25
US12209131B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
US12209131B2 (en) Anti-IL1RAP antibody compositions
EP3749346B1 (en) Antibody variable domain combinations targeting the nkg2d receptor
JP6794348B2 (ja) ヒト化抗ｏｘ４０抗体及びその使用
EP3778648A1 (en) Novel antibody molecule, and preparation method and use thereof
KR20220083770A (ko) Nkg2d, cd16 및 flt3에 결합하는 단백질
WO2021180205A1 (zh) Pvrig结合蛋白及其医药用途
CN112218686A (zh) 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
EP3583125A2 (en) Albumin binding domain fusion proteins
KR20200051789A (ko) Nkg2d, cd16, 및 c-유형 렉틴-유사 분자-1 (cll-1)에 결합하는 단백질
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
CN113004417A (zh) 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
JP2022542431A (ja) 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体
US9670276B2 (en) IL-1 binding proteins
KR20230005179A (ko) 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
KR20200038530A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
KR20250112921A (ko) Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
CN114907479B (zh) 抗cd112r抗体及其用途
CN111133007A (zh) 与胞外酶结合的重链抗体
KR20230166120A (ko) 새로운 tnfr2 결합 분자
US20230272095A1 (en) IL10Ra/IL2Ry SYNTHETIC CYTOKINES
TW202003854A (zh) 抗人ｌａｇ－３單克隆抗體及其應用
CN116199778B (zh) 抗4-1bb抗体及其用途
US20240383974A1 (en) Bispecific antibody and application thereof
JP2025527967A (ja) タンパク質結合ｎｋｇ２ｄ、ｃｄ１６、及びｃｅａｃａｍ５
JP2025518269A (ja) 抗ｃｄ４０抗体と抗ｐｄ－ｌ１×ｃｄ４０二重特異性抗体及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220803

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240312